June 1, 2023
Struggling to remain relevant.
One of the largest blunders in diabetes history was Teladoc buying Livongo for $19 Billion. This transaction occurred when digital health was hotter than Georgia asphalt. Thanks to COVID nearly every digital/virtual player was obtaining obscene valuations. Back then patients embraced digital/virtual options as they had no other choice. Back then we reminded everyone that if these companies were to survive over the long haul, they would need to prove their value once COVID went away.
Today these players are struggling to remain relevant as patients did what we expected them to do once COVID became less of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
